Published in JAMA Surg on May 01, 2013
Role of sentinel lymph node biopsy in patients with Merkel cell carcinoma: statistical analysis of 403 reported cases. Int J Clin Oncol (2014) 0.83
Hypopigmented atypical Spitzoid neoplasms (atypical Spitz nevi, atypical Spitz tumors, Spitzoid melanoma): a clinicopathological update. Dermatol Pract Concept (2015) 0.79
Predictors and Survival Impact of False-Negative Sentinel Nodes in Melanoma. Ann Surg Oncol (2015) 0.77
Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients. Medicine (Baltimore) (2015) 0.77
Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients. Ann Surg Oncol (2016) 0.75
Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. Cancer Med (2016) 0.75
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg (2005) 3.80
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol (1999) 3.74
A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery (1979) 2.65
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol (1998) 1.92
Head and neck melanoma. Cancer Control (2005) 1.61
Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Cancer (2010) 1.53
Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg (2001) 1.36
Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32
Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol (2009) 1.22
Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol (2004) 1.15
Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol (2011) 1.15
Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg (2008) 1.12
Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol (2009) 1.08
Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg (2002) 1.02
Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma. Head Neck (2010) 1.00
Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer (2011) 0.99
Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg (2010) 0.87
Does mitotic rate predict sentinel lymph node metastasis or survival in patients with intermediate and thick melanoma? Am J Surg (2010) 0.85
The definition of the sentinel lymph node in melanoma based on radioactive counts. Ann Surg Oncol (2002) 0.84
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Effects of limited work hours on surgical training. J Am Coll Surg (2002) 3.82
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. Intensive Care Med (2012) 3.68
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Slower walking speed forecasts increased postoperative morbidity and 1-year mortality across surgical specialties. Ann Surg (2013) 3.15
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res (2008) 2.38
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst (2003) 2.18
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst (2003) 1.92
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood (2008) 1.71
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells (2012) 1.70
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol (2007) 1.69
CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol (2007) 1.58
Efficacy and safety of a high protein, low carbohydrate diet for weight loss in severely obese adolescents. J Pediatr (2010) 1.57
Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol (2006) 1.53
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst (2002) 1.50
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs (2009) 1.47
Identification and recall of children with chronic medical conditions for influenza vaccination. Pediatrics (2004) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol (2011) 1.46
Cord blood transplant in childhood ALL. Pediatr Blood Cancer (2005) 1.43
Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.40
Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg (2008) 1.39
Effect of open access scheduling on missed appointments, immunizations, and continuity of care for infant well-child care visits. Arch Pediatr Adolesc Med (2006) 1.38
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol (2005) 1.37
Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med (2004) 1.35
Salivary cortisol in preterm infants: Validation of a simple method for collecting saliva for cortisol determination. Early Hum Dev (2007) 1.32
Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol (2006) 1.31
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol (2013) 1.28
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res (2013) 1.25
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer (2010) 1.24
Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat (2013) 1.24
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res (2010) 1.21
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19
Increased incidence and severity of diabetic ketoacidosis among uninsured children with newly diagnosed type 1 diabetes mellitus. Pediatr Diabetes (2005) 1.17
Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg (2011) 1.17
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res (2012) 1.16
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol (2012) 1.12
Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw (2015) 1.12
Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer (2007) 1.11
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs (2007) 1.09
Predictors of the duration of the respiratory syncytial virus season. Pediatr Infect Dis J (2009) 1.09
Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol (2005) 1.09
Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg (2005) 1.08
Melanoma, version 4.2014. J Natl Compr Canc Netw (2014) 1.07
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer (2010) 1.06
Facial fractures in children: unique patterns of injury observed by computed tomography. J Comput Assist Tomogr (2009) 1.06
Studies of lymphocyte reconstitution in a humanized mouse model reveal a requirement of T cells for human B cell maturation. J Immunol (2013) 1.06
Human intestinal lamina propria CD1c+ dendritic cells display an activated phenotype at steady state and produce IL-23 in response to TLR7/8 stimulation. J Immunol (2010) 1.05
Progression of aortic dilation in children with a functionally normal bicuspid aortic valve. Am J Cardiol (2006) 1.05
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol (2006) 1.03
A randomized controlled trial comparing a fascia iliaca compartment nerve block to a traditional systemic analgesic for femur fractures in a pediatric emergency department. Ann Emerg Med (2007) 1.03
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg (2013) 1.03
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.02
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer. Mol Oncol (2012) 1.01
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol (2009) 1.01
PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs (2008) 0.99
Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma. Am J Surg Pathol (2008) 0.98
Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg (2005) 0.98
HIV-1 infection of human intestinal lamina propria CD4+ T cells in vitro is enhanced by exposure to commensal Escherichia coli. J Immunol (2012) 0.98
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol (2009) 0.97
Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg (2005) 0.97
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res (2010) 0.96
Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. Cancer (2011) 0.96